Breast cancer is the most common malignancy in women worldwide. Patients with breast cancer are often diagnosed at later stages and have a strong desire for breast conservation, necessitating neoadjuvant chemotherapy. Tumors of different molecular subtypes and individual variations among patients lead to significant differences in treatment efficacy. Precise assessment of patients' responses to treatment regimens is imperative in advancing prognosis of breast cancer. In this study, 58 patients diagnosed with breast cancer and scheduled for neoadjuvant therapy will be recruited. Patient-derived organoids from their tumor biopsies will be utilized to evaluate the sensitivity of chemotherapy regimen. These drugs primarily include Doxorubicin, Carboplatin, Cyclophosphamide, Paclitaxel, as well as targeted therapies such as Herceptin and Pertuzumab.
Signed informed consent form and willingness to participate in the clinical study.
Female patients aged between 18 and 70 years old.
Confirmed early-stage breast cancer eligible for surgery (AJCC stages I to IIIA), with a tumor diameter of ≥ 2cm detected by MRI and without distant metastasis (M0).
ECOG performance status score of 0-1.
Received prior treatments.
Locally advanced breast cancer not amenable to surgery or inflammatory breast cancer (AJCC stage unresectable III).
Bilateral breast cancer.
Multiple breast cancers distributed in different quadrants.
Patients with breast cancer (AJCC stages I to IIIA) who need to receive neoadjuvant therapy.
Cohort
Prospective
Biopsy
Procedure/SurgeryBefore initiating neoadjuvant therapy, patients diagnosed with breast cancer undergo a tumor biopsy. The tissue obtained from the biopsy is utilized to establish organoids and conduct drug testing.
Correlation between drug sensitivity test results in patient-derived organoid models and clinical outcomes.
The drug sensitivity test results obtained from patient-derived organoid models will be compared with the clinical outcomes.
Comparison between drug sensitivity of organoid models and clinical imaging (MRI, ultrasound, BSGI) in predicting the efficacy of neoadjuvant chemotherapy.
The sensitivity and specificity would be checked between drug sensitivity of organoid models and clinical imaging (MRI, ultrasound, BSGI) in predicting the efficacy of neoadjuvant chemotherapy.
Click on the lead sponsor to view all of their trials.
